Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story [Yahoo! Finance]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: Yahoo! Finance
Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 70% efficacy. The trial did not meet its primary endpoint, mainly due to lower than expected Lyme disease incidence during the study. Despite this, the companies view the data as clinically meaningful and plan to move ahead with regulatory submissions. For investors watching NYSE:PFE, this vaccine update adds a fresh piece to the story around Pfizer beyond its established franchises. The stock trades at $26.77, with a 1 year return of 9.8%, a 3 year return showing a 20.2% decline, and a 5 year return showing a 6.2% decline. In that context, progress in under served areas such as Lyme disease helps illustrate how Pfizer is working to expand its vaccine portfolio. From here, regulatory review will be important, including how authorities weigh the 70% efficacy figure against the missed primary endpoint. If the vaccine eventually reaches the market, investors may track how it fits into
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNGlobeNewswire
- Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results [Yahoo! Finance]Yahoo! Finance
- Mixed results for Lyme disease vaccine hit Valneva shares [Yahoo! Finance]Yahoo! Finance
- Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss [CNBC]CNBC
- Valneva Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
VALN
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form 20-F
- 3/10/26 - Form SCHEDULE
- VALN's page on the SEC website